Skip to main content
. 2009 Jul 24;137(4):1498–1508.e5. doi: 10.1053/j.gastro.2009.07.051

Figure 3.

Figure 3

LSECtin inhibits T-cell immune responses in vitro. (A) Inhibition of T-cell activation by LSECtin–Fc. Peripheral blood T cells were stimulated with immobilized T-cell–specific mitogen anti-CD3 antibody plus 10 μg/mL or indicated concentration of LSECtin–Fc or human IgG. Cell activation was detected by staining with antibodies against cell surface activation molecules, including CD69 and CD25. (B) Inhibition of T-cell proliferation by LSECtin–Fc. T-cell proliferation was assayed by pulsing with bromodeoxyuridine (brdu). (C) Inhibition of cytokine production by LSECtin–Fc. IFN-γ, IL-2, IL-10, and transforming growth factor (tgf)-β concentrations in the supernatants was measured by enzyme-linked immunosorbent assay. (D) Inhibition of cytokine production by membrane-bound LSECtin. CHO cells stably expressing LSECtin were transfected with control siRNA or LSECtin siRNA and irradiated after 48 hours. PBMCs were co-cultured with the CHO cells together with the soluble anti-CD3 mAb for 48 hours. Cytokine expression in the supernatants was determined by enzyme-linked immunosorbent assay. (E) Inhibition of cytokine production by LSECtin–Fc in the presence of anti-CD28 antibody. (F) LSECtin–Fc inhibited cytokine production by DO11.10 CD4 T cells stimulated with OVA peptide 323-339. ★P < .05; ★★P < .01.